Multiple Sclerosis Center of Catalonia
Barcelona, 08035, Spain
NCT Number: NCT07178834
The goal of this clinical trial is to assessing safety and the occurrence of adverse effects during tele-rehabilitation (TRHB) in people with multiple sclerosis with an EDSS score of 6.5 or lower. The main questions it aims to answer are:
* Intervention using TRHB is considered safe and without adverse effects. * Intervention using TRHB has a high degree of self-adherence, an impact on physical activity levels and self-efficacy in exercise, and a positive effect on quality of life, mood, and perception of fatigue.
Researchers will compare the tele-rehabilitation with rehabilitation based solely on physical activity recommendations.
Participants will complete three weekly online rehabilitation sessions and must attend three follow-up visits.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Interventional
Not applicable
Barcelona, 08035, Spain
Multiple Sclerosis (MS) often entails a series of difficulties that cause some people to have high rates of absenteeism or even prevent them from benefiting from in-person rehabilitation treatments. The onset of the disease at a very young age, when the person is actively working or studying, the difficulty of balancing work and family life, mobility issues and lack of transportation, and geographical dispersion are some of the reasons why people with MS are not always able to access a neurorehabilitation center. Scientific evidence shows that functional and social barriers are the most common reasons why people do not adhere to rehabilitation. Home-based tele-rehabilitation (TRHB) is an alternative to rehabilitation in centers, allowing for remote supervision and the elimination of barriers. In addition, TRHB provides affected individuals and their families/caregivers with greater support in terms of care, mobility, and access to these services, and according to the World Health Organization (WHO), this type of assistance improves access to the healthcare system. There is a gap in research to identify the main adverse events related to tele-rehabilitation, and it is important to understand how adverse events, such as falls during physical therapy, are associated with the delivery of tele-rehabilitation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Adverse events are observed during online rehabilitation with computer vision technology in patients with MS.
Other names: Telerehabilitation, Intervention group
Time frame: From enrollment to the end of treatment in week 8
Adverse events such as falls, pain, fatigue, and others that may occur.
Time frame: (T1) baseline, (T2) after the 8 week, (T3) at 16 week.
Quality of life scale (Min.0; Max.100). The higher the score, the better.
Time frame: (T1) baseline, (T2) after the 8 week, (T3) at 16 week.
The scale measures walking speed. There are no minimum or maximum measurements. The higher the reading, the better.
Time frame: (T1) baseline, (T2) after the 8 week, (T3) at 16 week.
The scale measures capacity for effort. There are no minimum or maximum measurements. The higher the score, the better.
Time frame: (T1) baseline, (T2) after the 8 week, (T3) at 16 week.
The scale measures the level of balance. Minimum measurement 0; maximum 56. The higher the reading, the better.
Multiple Sclerosis Center of Catalonia
Other
Impact of a Tele-rehabilitation Program on People With Multiple Sclerosis: A Multicenter, Randomized, Single-blind Study.
Acronym: Telerehab
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04544436
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Cullman, Alabama, United States
View Trial DetailsNCT04548999
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Homewood, Alabama, United States
View Trial DetailsNCT06141473
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Birmingham, Alabama, United States
View Trial DetailsNCT07705581
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Graz, Austria
View Trial Details